Intercellular delivery of functional p53 by the herpesvirus protein VP22

Nature Biotechnology

Volumn 16, Issue 5, 1998, Pages 440-443

  Phelan, Anne ^a   Elliott, Gill ^a   O'Hare, Peter ^a  

^a MARIE CURIE RESEARCH INSTITUTE   (United Kingdom)

Author keywords

Gene therapy; Protein delivery; Protein engineering

Indexed keywords

CHIMERIC PROTEIN; PROTEIN P53; VIRUS PROTEIN;

APOPTOSIS; ARTICLE; CELL TRANSPORT; CYTOTOXICITY; GENE THERAPY; HERPES VIRUS; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN TARGETING; PROTEIN TRANSPORT; VIRION;

ANIMALS; APOPTOSIS; CELL NUCLEUS; CERCOPITHECUS AETHIOPS; COS CELLS; FLUORESCENT ANTIBODY TECHNIQUE; GENE THERAPY; HUMANS; MOLECULAR PROBE TECHNIQUES; SIMPLEXVIRUS; TRANSFECTION; TUMOR CELLS, CULTURED; TUMOR SUPPRESSOR PROTEIN P53; VERO CELLS; VIRAL FUSION PROTEINS; VIRAL PROTEINS;

EID: 0031953510     PISSN: 10870156     EISSN: None     Source Type: Journal    
DOI: 10.1038/nbt0598-440     Document Type: Article

References (18)

1. Verma, I. and Somia, N. 1997. Gene therapy-problems, promises and prospects. Nature 389:239-242.
2. Elliott, G. and O'Hare, P. 1997. Intercellular trafficking and protein delivery by a herpesvirus structural protein. Cell 88:223-233.
3. Levins, A.J. 1997. p53, the cellular gatekeeper for growth and division. Cell 88:323-331.
4. Diller, L, Kassel, J., Nelson, C.E., Gryka, M.A., Litwak, G., Gebhardt, M. et al. 1990. p53 functions as a cell cycle control protein in osteosarcomas. Mol. Cell Biol. 10:5772-5781.
5. Pientenpol, J.A. 1994. Sequence specific transcriptional transactivation is essential for growth suppression by p53. Proc. Natl. Acad. Scl. USA 91:1998-2002.
6. Baker. S.J., Markowitz, S., Fearon, E.R., Willson, J.K.V., and Vogelstein, B. 1990. Suppression of human colorectal carcinoma cell growth by wild type p53. Science 249:912-915.
7. Hamada, K., Alemany, R., Zhang, W.-W., Hittelman, W.N., Lotan, R., Roth, U.A., and Mitchell, M.F. 1996. Adenovirus-mediated transfer of a wild type p53 gene and induction of apoptosis in cervical cancer. Cancer Res. 56:3047-3054.
8. Nielsen, L.L., Dell, J., Maxwell, E., Armstrong, L, Maneval, D., and Catino, J.J. 1997. Efficacy of p53 adenovirus mediated gene therapy against human breast cancer xenografts. Cancer Gene Ther. 4:129-138.
9. Xu, M., Kumar. X.M., Srinivas, S., Detolla, L.J., Yu, S.F., Stass, S.A., and Mixson, A.J. 1997. Parental gene therapy with p53 inhibits human breast cancer tumors in vivo through a bystander effect without evidence of toxicity. Hum. Gene Ther. 8:177-185.
10. Roth, J.A. 1996. Retrovirus-mediated wild type p53 gene transfer to tumors of patients with lung cancer. Nat. Med. 2:985-991.
11. Cai, D.W. 1993. Stable expression of the wild type p53 gene in human lung cancer cells after retrovirus-mediated gene transfer. Hum. Gene Ther. 4:617-624.
12. Sandig, V., Brand, K., Herwig, S., Lukas, J., Bartek, J., and Strauss, S. 1997. Adenovirally transferred p16 and p53 genes cooperate to induce apoptotic tumor death. Nat. Med. 3:313-319.
13. Qazilbash, M.H., Xiao, X., Seth, P., Cowan, K.H., and Walsh, C.E. 1997. Cancer gene therapy using a novel adeno-associated virus vector expressing human wild type p53. Gene Ther. 4:675-682.
14. Mesnil, M., Piccoli, C., Tiraby, G., Willecke, K., and Yamasaki, H. 1996. Bystander killing of cancer cells by herpes simplex virus thymidine kinase gene is mediated by connexins. Proc. Natl. Acad. Sci. USA 93:1831-1835.
15. Elliott. G.D. and Meredith, D. 1994. The herpes simplex virus type 1 tegument protein VP22 is encoded by gene UL49. J. Gen. Wol. 73:723-726.
16. Leslie, J., Rixon, F., and McLauchlan, J. 1997. Overexpression of the herpes simplex virus type 1 tegument protein VP22 increases its incorporation into virus particles. Virology 220:60-68.
17. McLauchlan, J., Liefkins, K., and Stow, N.D. 1994. The herpes simplex virus type 1 UL37 gene product is a component of virus particles. J. Gen. Wol. 75:2047-2052.
18. Harlow, E., Crawford, L.V., Pirn, D.C., and Williamson, N.M. 1981. Monoclonal antibodies specific for simian virus 40 tumor antigens. J. Wol. 39:861-869.